Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Trial Tragedy: Janssen Halts FAAH Inhibitor Trial

This article was originally published in Scrip

Executive Summary

Janssen has voluntarily suspended dosing in two Phase II studies of its experimental FAAH inhibitor JNJ-42165279; the drug is in the same class as the compound at the heart of the clinical trial tragedy in France.

You may also be interested in...



FAAH Inhibitor Trials Could Resume In US Following French Study Disaster Review

Bial-Portela's drug had 'unique toxicity' not found with other compounds in the class, FDA says; findings could allow studies of Janssen's and Pfizer's investigational FAAH inhibitors that have been on hold to proceed.

10 US Approval Decisions To Look Out For In Q3

This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.

Sanofi Creates ‘Center Of Excellence’ In Pursuit Of mRNA Vaccine Rivals

Sanofi is beefing up its investment in mRNA vaccine technology with a 400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.

Topics

UsernamePublicRestriction

Register

SC064284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;